ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,064.97
      -1.00%
      US Tech 100
      17,127.80
      -1.05%
      Dow Jones
      37,950.01
      -1.14%
      Brent Oil
      86.165
      -1.28%
      Bitcoin
      60,057.46
      -5.92%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Halozyme Therapeutics Incorporated (HALO)

      7. Halozyme Therapeutics Incorporated (HALO) News

      HALO

      Halozyme Therapeutics (HALO)

      Halozyme Therapeutics Incorporated
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:HALO
      DateTimeSourceHeadlineSymbolCompany
      12:53PMiHub NewswireFeaturedCannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia
      04/25/20244:45PMPR Newswire (US)Mahesh Krishnan Elected to Halozyme's Board of DirectorsNASDAQ:HALOHalozyme Therapeutics Incorporated
      04/23/20248:30AMPR Newswire (US)Halozyme to Report First Quarter 2024 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
      03/04/20244:13PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/28/20246:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/28/20244:07PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/27/20245:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/27/20245:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/27/20245:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/27/20244:08PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/27/20248:30AMPR Newswire (US)Halozyme to Participate in Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/20/20246:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/20/20246:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/20/20246:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/20/20246:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/20/20244:07PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HALOHalozyme Therapeutics Incorporated
      02/20/20244:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/20/20244:01PMPR Newswire (US)HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/16/20245:47PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/16/20245:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/16/20245:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/13/20244:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/13/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/13/20244:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      02/12/20246:19AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:HALOHalozyme Therapeutics Incorporated
      02/08/20244:30PMPR Newswire (US)Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
      01/29/20244:15PMPR Newswire (US)Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NASDAQ:HALOHalozyme Therapeutics Incorporated
      01/23/202411:52AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:HALOHalozyme Therapeutics Incorporated
      01/18/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
      01/18/20248:30AMPR Newswire (US)Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia GravisNASDAQ:HALOHalozyme Therapeutics Incorporated
       Showing the most relevant articles for your search:NASDAQ:HALO